BR112015031903A2 - composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto - Google Patents
composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um compostoInfo
- Publication number
- BR112015031903A2 BR112015031903A2 BR112015031903A BR112015031903A BR112015031903A2 BR 112015031903 A2 BR112015031903 A2 BR 112015031903A2 BR 112015031903 A BR112015031903 A BR 112015031903A BR 112015031903 A BR112015031903 A BR 112015031903A BR 112015031903 A2 BR112015031903 A2 BR 112015031903A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Abstract
resumo composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto a presente invenção se refere aos compostos que são moduladores do receptor de estrogênio. a presente invenção também se refere às composições e medicamentos farmacêuticos que incluem os compostos descritos no presente, bem como aos métodos de utilização de tais moduladores do receptor de estrogênio, isoladamente e em combinação com outros compostos, para o tratamento de doenças ou condições que são mediadas ou dependentes dos receptores de estrogênio.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361836901P | 2013-06-19 | 2013-06-19 | |
US201461952430P | 2014-03-13 | 2014-03-13 | |
PCT/US2014/043040 WO2014205138A1 (en) | 2013-06-19 | 2014-06-18 | Estrogen receptor modulator and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015031903A2 true BR112015031903A2 (pt) | 2017-07-25 |
BR112015031903A8 BR112015031903A8 (pt) | 2019-12-31 |
Family
ID=52105249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015031903A BR112015031903A8 (pt) | 2013-06-19 | 2014-06-18 | composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto |
Country Status (20)
Country | Link |
---|---|
US (2) | US9873684B2 (pt) |
EP (1) | EP3010501B1 (pt) |
JP (2) | JP6576916B2 (pt) |
KR (1) | KR20160021277A (pt) |
CN (1) | CN105324115B (pt) |
AU (1) | AU2014281511A1 (pt) |
BR (1) | BR112015031903A8 (pt) |
CA (1) | CA2912853A1 (pt) |
CL (1) | CL2015003456A1 (pt) |
CR (1) | CR20150664A (pt) |
EA (1) | EA031077B1 (pt) |
HK (1) | HK1214532A1 (pt) |
IL (1) | IL242611B (pt) |
MX (1) | MX2015017655A (pt) |
PE (1) | PE20160157A1 (pt) |
PH (1) | PH12015502621A1 (pt) |
SG (1) | SG11201509508YA (pt) |
TW (1) | TW201501710A (pt) |
UA (1) | UA117249C2 (pt) |
WO (1) | WO2014205138A1 (pt) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009061345A2 (en) | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Targeting cdk4 and cdk6 in cancer therapy |
KR20160021277A (ko) * | 2013-06-19 | 2016-02-24 | 세라곤 파마슈티컬스, 인크. | 에스트로겐 수용체 조절제 및 이의 용도 |
JP6389517B2 (ja) | 2013-06-19 | 2018-09-12 | セラゴン ファーマシューティカルズ, インク. | アゼチジンエストロゲン受容体調節因子及びその使用 |
EP2862880A1 (en) | 2013-10-16 | 2015-04-22 | Solvay Acetow GmbH | Acylation process |
CN106572990A (zh) * | 2014-03-13 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 含有***受体调节剂的治疗性组合产品 |
HUE046567T2 (hu) | 2014-03-13 | 2020-03-30 | Univ Indiana Res & Tech Corp | Hepatitis B mag protein allosztérikus modulátorok |
CA2941161A1 (en) | 2014-03-13 | 2015-09-17 | F.Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
WO2016097071A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
EP3233852B1 (en) | 2014-12-18 | 2020-07-15 | F. Hoffmann-La Roche AG | Tetrahydro-pyrido[3,4-b]indoles as estrogen receptor modulators and uses thereof |
EP3233818A1 (en) * | 2014-12-18 | 2017-10-25 | F. Hoffmann-La Roche AG | Derivatives of 2,3-diphenylchromene useful for the treatment of cancer |
CN113024466A (zh) | 2015-05-29 | 2021-06-25 | 卫材 R&D 管理有限公司 | 四取代的烯烃化合物及其用途 |
WO2017024319A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
TWI721016B (zh) | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
HUE055321T2 (hu) | 2015-10-01 | 2021-11-29 | Olema Pharmaceuticals Inc | Tetrahidro-1H-pirido[3,4-b]indol anti-ösztrogén hatóanyagok |
HUE059386T2 (hu) | 2015-10-27 | 2022-11-28 | Sun Pharma Advanced Res Co Ltd | Új heterociklusos antiösztrogének |
PT3386500T (pt) | 2015-12-09 | 2023-01-06 | Univ Illinois | Supressores seletivos do recetor de estrogénio à base de benzotiofeno |
WO2017182493A1 (en) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
EP3454862A4 (en) | 2016-05-10 | 2020-02-12 | C4 Therapeutics, Inc. | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
EP3478294A4 (en) | 2016-07-01 | 2020-06-10 | G1 Therapeutics, Inc. | PYRIMIDINE-BASED ANTIPROLIFERATIVE ACTIVE SUBSTANCES |
TW201815789A (zh) | 2016-07-25 | 2018-05-01 | 瑞典商阿斯特捷利康公司 | 化合物 |
CN109937201A (zh) | 2016-09-15 | 2019-06-25 | 组装生物科学股份有限公司 | 乙型肝炎核心蛋白调节剂 |
JP2020011901A (ja) * | 2016-10-20 | 2020-01-23 | 協和キリン株式会社 | ピロリジン化合物の製造方法 |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
HRP20220255T1 (hr) | 2016-10-24 | 2022-04-29 | Astrazeneca Ab | Derivati 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izokinolina koji su korisni u liječenju raka |
JP2019532999A (ja) * | 2016-11-04 | 2019-11-14 | ジェネンテック, インコーポレイテッド | Her2陽性乳がんの治療 |
SG11201903795WA (en) | 2016-11-28 | 2019-05-30 | Eisai R&D Man Co Ltd | Salts of indazole derivative and crystals thereof |
WO2018108954A1 (en) | 2016-12-12 | 2018-06-21 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol |
KR102576011B1 (ko) | 2017-01-06 | 2023-09-06 | 쥐원 쎄라퓨틱스, 인크. | 암의 치료를 위한 조합 요법 |
CN110214140B (zh) | 2017-01-30 | 2022-08-30 | 阿斯利康(瑞典)有限公司 | ***受体调节剂 |
CN111386263A (zh) | 2017-02-08 | 2020-07-07 | 达纳-法伯癌症研究所有限公司 | 调节嵌合抗原受体 |
CA3052810A1 (en) | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
BR112019018230A2 (pt) | 2017-03-02 | 2020-07-21 | Assembly Biosciences, Inc. | compostos de sulfamida cíclica e métodos de sua utilização |
WO2018169907A1 (en) | 2017-03-13 | 2018-09-20 | Assembly Biosciences, Inc. | Process for making hepatitis b core protein modulators |
EA201992768A1 (ru) | 2017-06-29 | 2020-05-19 | Г1 Терапьютикс, Инк. | Морфологические формы g1t38 и способы их получения |
EP3697436A1 (en) | 2017-10-18 | 2020-08-26 | Novartis AG | Compositions and methods for selective protein degradation |
JP2021503448A (ja) | 2017-11-16 | 2021-02-12 | ノバルティス アーゲー | Lsz102及びリボシクリブを含む医薬組合せ |
JP2021504384A (ja) * | 2017-12-01 | 2021-02-15 | ノバルティス アーゲー | Lsz102及びアルペリシブを含む医薬品の組合せ |
CN110343101B (zh) * | 2018-04-04 | 2022-07-12 | 青岛福沃药业有限公司 | 用于治疗乳腺癌的***受体降解剂 |
WO2019245974A1 (en) | 2018-06-21 | 2019-12-26 | Genentech, Inc. | Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use |
EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
PE20221588A1 (es) | 2019-07-22 | 2022-10-10 | Sun Pharma Advanced Res Co Ltd | Degradador selectivo del receptor de estrogeno |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
CN115872996B (zh) * | 2023-02-21 | 2023-05-05 | 山东绿叶制药有限公司 | 一种***受体降解剂化合物及其制备方法和应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
DE3684446D1 (de) | 1985-12-28 | 1992-04-23 | Sumitomo Pharma | Arzneimittel mit verzoegerter stossweiser freisetzung. |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
US6060503A (en) * | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
US5407947A (en) * | 1993-11-05 | 1995-04-18 | Eli Lilly And Company | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
US6262270B1 (en) * | 1998-08-14 | 2001-07-17 | Schering Corporation | Enantioselective synthesis |
EP1237925B1 (en) | 1999-12-07 | 2007-07-11 | Sumitomo Chemical Company, Limited | Mutant er-alpha and test systems for transactivation |
DE10013782A1 (de) | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
CA2435775A1 (en) | 2001-01-24 | 2002-08-01 | Chiesi Farmaceutici S.P.A. | 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
US7105679B2 (en) | 2001-12-19 | 2006-09-12 | Kanojia Ramesh M | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
WO2004091488A2 (en) | 2003-04-14 | 2004-10-28 | Merck & Co., Inc. | Estrogen receptor modulators |
HUE033581T2 (hu) * | 2010-06-10 | 2017-12-28 | Seragon Pharmaceuticals Inc | Ösztrogén receptor modulátorok és alkalmazásaik |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
SG10202110077QA (en) * | 2011-10-14 | 2021-10-28 | Genentech Inc | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
WO2013056178A2 (en) | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Novel estrogen receptor mutations and uses thereof |
WO2013090829A1 (en) * | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
NZ630124A (en) | 2012-03-20 | 2016-01-29 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
CA2873882C (en) * | 2012-04-05 | 2020-12-15 | Boehringer Ingelheim International Gmbh | 1,8-naphthyridin-2(1h)-one derivatives as cytomegalovirus inhibitors |
RU2015138964A (ru) | 2013-03-14 | 2017-04-18 | Серагон Фармасьютикалз, Инк. | Полициклические модуляторы рецептора эстрогена и их применения |
JP6389517B2 (ja) | 2013-06-19 | 2018-09-12 | セラゴン ファーマシューティカルズ, インク. | アゼチジンエストロゲン受容体調節因子及びその使用 |
KR20160021277A (ko) * | 2013-06-19 | 2016-02-24 | 세라곤 파마슈티컬스, 인크. | 에스트로겐 수용체 조절제 및 이의 용도 |
CA2932106A1 (en) | 2013-12-06 | 2015-06-11 | F. Hoffmann-La Roche Ag | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
CN106572990A (zh) | 2014-03-13 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 含有***受体调节剂的治疗性组合产品 |
CA2941161A1 (en) | 2014-03-13 | 2015-09-17 | F.Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
MX2017000795A (es) | 2014-07-18 | 2017-08-07 | Williams Scotsman Inc | Sistema de conexión de paneles de pared para unidades de construcción modulares. |
EP3233818A1 (en) | 2014-12-18 | 2017-10-25 | F. Hoffmann-La Roche AG | Derivatives of 2,3-diphenylchromene useful for the treatment of cancer |
WO2016097071A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
-
2014
- 2014-06-18 KR KR1020167001338A patent/KR20160021277A/ko not_active Application Discontinuation
- 2014-06-18 AU AU2014281511A patent/AU2014281511A1/en not_active Abandoned
- 2014-06-18 SG SG11201509508YA patent/SG11201509508YA/en unknown
- 2014-06-18 EA EA201592214A patent/EA031077B1/ru not_active IP Right Cessation
- 2014-06-18 CA CA2912853A patent/CA2912853A1/en not_active Abandoned
- 2014-06-18 MX MX2015017655A patent/MX2015017655A/es unknown
- 2014-06-18 BR BR112015031903A patent/BR112015031903A8/pt not_active Application Discontinuation
- 2014-06-18 EP EP14812952.1A patent/EP3010501B1/en active Active
- 2014-06-18 WO PCT/US2014/043040 patent/WO2014205138A1/en active Application Filing
- 2014-06-18 PE PE2015002634A patent/PE20160157A1/es unknown
- 2014-06-18 JP JP2016521557A patent/JP6576916B2/ja active Active
- 2014-06-18 CN CN201480035316.2A patent/CN105324115B/zh active Active
- 2014-06-18 UA UAA201600246A patent/UA117249C2/uk unknown
- 2014-06-19 TW TW103121277A patent/TW201501710A/zh unknown
-
2015
- 2015-11-16 IL IL242611A patent/IL242611B/en not_active IP Right Cessation
- 2015-11-24 CL CL2015003456A patent/CL2015003456A1/es unknown
- 2015-11-24 PH PH12015502621A patent/PH12015502621A1/en unknown
- 2015-12-09 US US14/963,658 patent/US9873684B2/en active Active
- 2015-12-16 CR CR20150664A patent/CR20150664A/es unknown
-
2016
- 2016-03-08 HK HK16102620.6A patent/HK1214532A1/zh unknown
-
2017
- 2017-06-12 US US15/620,304 patent/US10227334B2/en active Active
-
2019
- 2019-03-13 JP JP2019045520A patent/JP2019142871A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20160021277A (ko) | 2016-02-24 |
TW201501710A (zh) | 2015-01-16 |
CN105324115B (zh) | 2019-01-04 |
WO2014205138A1 (en) | 2014-12-24 |
EP3010501A4 (en) | 2017-02-01 |
US20160090378A1 (en) | 2016-03-31 |
EA201592214A1 (ru) | 2016-06-30 |
EP3010501A1 (en) | 2016-04-27 |
BR112015031903A8 (pt) | 2019-12-31 |
JP2016523253A (ja) | 2016-08-08 |
CA2912853A1 (en) | 2014-12-24 |
CR20150664A (es) | 2016-01-29 |
US10227334B2 (en) | 2019-03-12 |
CN105324115A (zh) | 2016-02-10 |
PE20160157A1 (es) | 2016-03-18 |
AU2014281511A1 (en) | 2015-12-03 |
HK1214532A1 (zh) | 2016-07-29 |
CL2015003456A1 (es) | 2016-07-29 |
EP3010501B1 (en) | 2021-11-03 |
MX2015017655A (es) | 2016-04-15 |
US9873684B2 (en) | 2018-01-23 |
UA117249C2 (uk) | 2018-07-10 |
US20170275273A1 (en) | 2017-09-28 |
JP6576916B2 (ja) | 2019-09-18 |
SG11201509508YA (en) | 2015-12-30 |
PH12015502621A1 (en) | 2016-03-07 |
IL242611B (en) | 2018-10-31 |
JP2019142871A (ja) | 2019-08-29 |
EA031077B1 (ru) | 2018-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015031903A2 (pt) | composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto | |
BR112015022566A2 (pt) | composto e composição farmacêutica | |
BR112015030595A2 (pt) | moduladores de receptor de estrogênio de azetidina e usos dos mesmos | |
BR112017007662A8 (pt) | Composto, composição farmacêutica e uso de um composto | |
BR112014014124A2 (pt) | Moduladores do receptor de estrogênio fluorados e usos dos mesmos | |
BR112017002053A2 (pt) | composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto | |
BR112013006395A2 (pt) | moduladores do receptor de estrogênio e seus usos. | |
PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
EA201270815A1 (ru) | Модуляторы рецепторов эстрогена и их применение | |
BR112012007102A2 (pt) | compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico | |
BR112012020558A2 (pt) | moduladores do receptor de androgênio e seus usos | |
BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
BR112017007123A2 (pt) | derivados de tetrahidroisoquinolina | |
CR20140144A (es) | Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
BR112015010791A2 (pt) | moduladores de gpr40 de di-hidropirazol | |
DOP2015000005A (es) | Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
BR112015030387A2 (pt) | compostos de pirazol como moduladores de fshr e usos dos mesmos | |
EA201591196A1 (ru) | Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств | |
BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
BR112013030391A2 (pt) | derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina | |
EA201501163A1 (ru) | Модуляторы рецептора cxcr7 | |
BR112017013998A2 (pt) | novos derivados de benzimidazol como agentes anti-histamínicos | |
BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |